GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Current Deferred Revenue

Haleon (XTER:H6D0) Current Deferred Revenue : €0 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Haleon Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Haleon's current deferred revenue for the quarter that ended in Mar. 2024 was €0 Mil.

Haleon Current Deferred Revenue Historical Data

The historical data trend for Haleon's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Current Deferred Revenue Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - - -

Haleon Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Haleon Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Haleon's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon (XTER:H6D0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Current Deferred Revenue
Comparable Companies
LSE:HIK LSE:HCM LSE:INDV LSE:BMK LSE:APH LSE:ANCR LSE:EAH LSE:AGY LSE:CEL LSE:STX ZTS XTER:MRK TSE:4502 NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NBIX
Traded in Other Exchanges
HLNCF:USA HLN:USA HLN1:Mexico HLNl:UK HLN:UK
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Website
https://www.haleon.com
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Haleon (XTER:H6D0) Headlines

No Headlines